|2026年7月23日星期四| NO.1信达生物:全球首款口服周制剂小分子GLP-1申报临床 7月21日,信达生物IBI3042的临床试验申请获国家药监局受理。今年6月,公司已在美国糖尿病学会(ADA)年会上披露了包括IBI3042在内的多项代谢管线数据。IBI3042为一款新型口服小分子GLP-1(胰高血糖素样肽-1)受体激动剂,这也是全球范围内首款进入临床阶段的口服周制剂小分子GLP-1。...
Source Link|2026年7月23日星期四| NO.1信达生物:全球首款口服周制剂小分子GLP-1申报临床 7月21日,信达生物IBI3042的临床试验申请获国家药监局受理。今年6月,公司已在美国糖尿病学会(ADA)年会上披露了包括IBI3042在内的多项代谢管线数据。IBI3042为一款新型口服小分子GLP-1(胰高血糖素样肽-1)受体激动剂,这也是全球范围内首款进入临床阶段的口服周制剂小分子GLP-1。...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.